Answers are grounded in this paper and cite their sources.
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is the standard treatment for neovascular age-related macular degeneration (nAMD), a leading cause of irreversible central vision loss in older adults.Frequent injections and visits burden patients, caregivers, and clinics, and treat-and-extend (T&E) dosing, which individualizes the interval between injections, may reduce that burden.The study aimed to compare 12-month visual outcomes of T&E with fixed-interval dosing of the same anti-VEGF agent in treatment-naïve adults with nAMD, against a non-inferiority margin of five Early Treatment Diabetic Retinopathy Study (ETDRS) letters.Randomized trials were identified by a targeted (nonsystematic) search; screening, data extraction and risk-of-bias assessment were done by one reviewer, and the review was not prospectively registered.Mean differences in best-corrected visual acuity (BCVA) change were pooled by random-effects meta-analysis (REML with Hartung-Knapp confidence intervals) and reported separately by comparator (monthly versus bimonthly/8-weekly).Five randomized trials were pooled (1,536 participants in the compared arms).The pooled difference was 0.1 letters (95% CI -2.4 to 2.6; 95% prediction interval -6.4 to 6.6; I² = 56%).Against monthly ranibizumab (three trials), the difference was 0.5 letters (95% CI -5.5 to 6.4; I² = 77%), and T&E used 2.4 to 2.9 fewer injections in year one.Against bimonthly or 8-weekly dosing (two trials), the difference was -0.8 letters (95% CI -4.6 to 2.9), and T&E used 1.7 to 1.9 more injections.Certainty of evidence was low.Pooled 12-month visual outcomes with T&E were compatible with non-inferiority to fixed dosing (lower confidence limit above -5 letters), but this does not establish equivalence: the prediction interval extends beyond the margin, and the monthly-comparator interval alone could not exclude a five-letter disadvantage.Injection savings were seen only against monthly dosing.Because of the targeted search, single-reviewer process, and absence of prospective registration, these findings are provisional pending a systematic multidatabase review.
No takes yet. Share an insight, caveat, or question.
Nawar K Alkhalifa (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: